The global Acute Lymphocytic Leukemia Therapeutics market size is expected to be worth around US$ 13.4 billion by 2030, according to a new report by Vision Research Reports.
The global Acute Lymphocytic Leukemia Therapeutics market size was valued at US$ 1.5 billion in 2020 and is anticipated to grow at a CAGR of 20.0 % during forecast period 2021 to 2030.
Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.
Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.
Treatment of ALL consists of various therapies such as chemotherapy, targeted therapy, radiation therapy, and stem cell transplant. Chemotherapy segment dominated the market in 2016 owing to factors such as its ability to destroy leukemia cells and prevent thriving & multiplication of cancerous cells that impede the progress of disease. All these factors are responsible for the increase in prescription rate of chemotherapy over the last two decades. In chemotherapy, single or combination drugs (chemotherapy regimen) are used for treating ALL. This therapy includes cytotoxic agents, antimetabolites, alkylating agents, and other plant derivatives. Moreover, stem cell transplant can be used together with chemotherapy, which helps healthcare practitioners induce chemotherapy infusions at high doses for effective treatment.
Targeted therapy is the fastest growing segment over the forecast period. This therapy offers benefits such as higher precision and efficiency of treatment with faster recovery in comparison to chemotherapy. Furthermore, increasing preference for targeted therapies for the treatment of this condition is the driving force of the market.
ALL is classified into three types-Philadelphia (Ph) chromosome, precursor B-ALL, and T-cell ALL. The Philadelphia (Ph) chromosome is further classified into Ph-positive ALL and Ph-negative ALL. The chances of acquiring this disease increase with age.The drugs used for treatment of ALL are usually tyrosine kinase inhibitors such as dasatinib (Sprycel), imatinib (Glivec), and nilotinib (Tasigna). The above-mentioned drug has multiple indication with acute lymphoblastic leukemia as one of them. Usually, the drug used to treat chronic myeloid leukemia exhibits the potential to treat acute lymphoblastic leukemia as well.
The precursor B-ALL segment dominated the market in 2016 owing to its high development rate in early stages and high incidence. This segment is also expected to witness the fastest growth during the forecast period due to increasing prevalence of this condition in adults. According to National Comprehensive Cancer Network (NCCN), B-cell ALL subtype starts in young cells that develops in bone marrow and eventually become mature B-cell (B-lymphocytes) leading to a condition known as Burkitt type ALL (mature B-ALL). It is the most commonly occurring subtype of ALL. Precursor B-cell ALL is further classified into BCR-ABL gene and mature B-cell (Burkitt type). It accounts for 4% of total ALL cases.
North America dominated the market in 2016. Presence of key manufacturers in the U.S. and well-established healthcare infrastructure are some of the factors responsible for its large share. Moreover, the U.S. is anticipated to witness substantial growth due to the launch of the drug, besponsa (inotuzumab ozogamicin), in August 2017 and presence of strong pipeline drugs such as eryaspase (asparaginase), which is under phase II of clinical trials.
Asia Pacific is anticipated to witness the fastest growth with a lucrative CAGR of 10.8% during the forecast period owing to high unmet clinical needs, rising disposable income, availability of effective treatment, and rising awareness about early diagnosis in emerging countries, such as China and India.
Erytech Pharma; Spectrum Pharmaceuticals, Inc.; Pfizer, Inc.; Sigma-Tau s.p.a.; and Genzyme Corporation.
CALGB 8811 regimen
Nucleoside Metabolic Inhibitors
Stem cell transplantation
Precursor B-cell ALL
The Acute Lymphocytic Leukemia Therapeutics market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Acute Lymphocytic Leukemia Therapeutics market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Acute Lymphocytic Leukemia Therapeutics market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Acute Lymphocytic Leukemia Therapeutics market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Acute Lymphocytic Leukemia Therapeutics market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Acute Lymphocytic Leukemia Therapeutics capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Acute Lymphocytic Leukemia Therapeutics by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Acute Lymphocytic Leukemia Therapeutics market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Acute Lymphocytic Leukemia Therapeutics market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Acute Lymphocytic Leukemia Therapeutics market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Acute Lymphocytic Leukemia Therapeutics industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Acute Lymphocytic Leukemia Therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Acute Lymphocytic Leukemia Therapeutics market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Acute Lymphocytic Leukemia Therapeutics market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Acute Lymphocytic Leukemia Therapeutics market. These factors have benefited the growth of the global market for Acute Lymphocytic Leukemia Therapeutics. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Acute Lymphocytic Leukemia Therapeutics. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Acute Lymphocytic Leukemia Therapeutics are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Retinal Disorders Treatment Market (By Indication: Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, and Others; By Therapeutic Class; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Dystrophic Epidermolysis Bullosa Treatment Market (By Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, Others; By Disease Type: DDEB and RDEB; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Bromelain Market (By Application: Food & Beverages, Healthcare & Pharmaceuticals, Cosmetics, and Other Industries; By Source: Stem and Fruit) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Chronic Idiopathic Constipation Treatment Market (By Drug Class: Serotonin-4 [5-Ht4] Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants, Others; By Route of Administration: Oral and Rectal; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Hemoglobin Feed Market (By Source: Bovine, Swine, Poultry, Shark, Synthetic, Others; By Application: Industrial and Commercial) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...